Microarrays MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ProductBy End-useBy ApplicationBy Technology

Microarrays are solid-support platforms, typically glass slides, silicon chips or bead-based formats, that hold thousands of immobilized DNA, protein or peptide probes arranged in a fixed grid to allow parallel detection of genetic or protein targets in a single sample. They are used to profile gene expression, genotype variants, screen protein interactions and support companion diagnostic panels. Buyers include pharmaceutical and biotechnology companies conducting drug discovery research, academic and government research institutes, and diagnostic laboratories running hereditary, oncology or infectious disease panels.

The global microarrays market stood at USD 1.65 billion in 2025. A forecast-period rate of 6.8% takes it to USD 2.98 billion by 2034, and the study reports every year in between, passing USD 1.15 billion in 2020, USD 1.53 billion in 2024, USD 1.76 billion in 2026 and USD 2.29 billion in 2030.

37.58% of 2025 revenue sits in DNA Microarrays, worth USD 0.62 billion and rising to USD 1.01 billion at 33.89% by 2034, the largest type line in both years. Growth is fastest in Tissue Microarrays at 8.56% and slowest in MM Chips at 4.4%. Protein Microarrays, Peptide Microarrays and Tissue Microarrays take share over the period; DNA Microarrays, MM Chips, Cellular Microarrays and Other give it up while still growing in absolute terms.

Cut by product, the largest line is Consumables: 58.18% of 2025 revenue, worth USD 0.96 billion, and 56.04% at USD 1.67 billion by 2034. Software and services grows faster at 10.22% against 6.34%, moving from 12.12% of revenue to 16.11% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views, not components.

North America is the largest region at 41.9% of 2025 revenue, worth USD 0.69 billion and reaching USD 1.13 billion by 2034. Europe follows at 26.9%, moving from USD 0.44 billion to USD 0.75 billion, and Middle East and Africa is the smallest at 3.7%. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.

Behind these figures sit five regions, seven type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

• The global microarrays market moves from USD 1.15 billion in 2020 to USD 1.65 billion in 2025 and USD 2.98 billion by 2034, the forecast period compounding at 6.8% a year.
• 37.58% of 2025 revenue sits in DNA Microarrays (USD 0.62 billion) and it remains the largest type line in 2034 at USD 1.01 billion and 33.89%.
• At 8.56%, Tissue Microarrays grows faster than any other type line, moving from USD 0.13 billion and 7.88% of revenue in 2025 to USD 0.27 billion and 9.06% in 2034.
• The bull case puts 2034 revenue at USD 3.4 billion and the bear case at USD 2.56 billion, either side of the USD 2.98 billion base case, each with its own stated assumption in the full report.
• North America holds 41.9% of global revenue in 2025 at USD 0.69 billion, the largest of the five regions tracked, and reaches USD 1.13 billion by 2034.
• The United States accounts for 88.41% of North America in the base year, worth USD 0.61 billion in 2025 and reaching USD 0.99 billion by 2034, the worked country example carried through that region's chapters.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three movements define the forecast period in the global microarrays market: how the type mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Tissue Microarrays grows faster than MM Chips. Between 2026 and 2034, 8.56% growth in Tissue Microarrays against 4.4% in MM Chips pulls the type mix apart. Over the forecast period that moves Tissue Microarrays from 7.88% of revenue to 9.06%, and MM Chips from 10.3% to 8.05%. The revenue figures behind that are USD 0.13 billion to USD 0.27 billion and USD 0.17 billion to USD 0.24 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Growth concentrates in Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 22.9% of revenue in 2025 to 28% in 2034, worth USD 0.38 billion rising to USD 0.83 billion; Latin America moves from 4.7% of revenue in 2025 to 5% in 2034, worth USD 0.08 billion rising to USD 0.15 billion; Middle East and Africa moves from 3.7% of revenue in 2025 to 4% in 2034, worth USD 0.06 billion rising to USD 0.12 billion. Share moves off the others in turn: North America at 41.9% moving to 38%, Europe at 26.9% moving to 25%, each still growing in revenue terms. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

Growth compounds at 6.8% without a step change. The market moves through USD 1.15 billion in 2020, USD 1.53 billion in 2024, USD 1.65 billion in 2025, USD 1.76 billion in 2026, USD 2.29 billion in 2030 and USD 2.98 billion in 2034. The forecast rate of 6.8% sits against 7.49% over the historical period, so the projection extends an observed trend instead of proposing a new one. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the type and regional sections come in.

Tissue Microarrays adds the most incremental growth

Separate the 6.8% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.

The bear case and what drives it

What the bull case turns on

Revenue is concentrated in DNA Microarrays

North America holds 41.9% of the global microarrays market in 2025, worth USD 0.69 billion on the way to USD 1.13 billion by 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

By 2034 the share stands at 38%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

DNA Microarrays leads here as it does globally, at 37.58% of 2025 revenue, and Tissue Microarrays again grows fastest at 8.56%. North America is reported axis by axis and country by country in the full study.

88.41% of North America's base-year revenue comes from the United States; USD 0.61 billion, rising to USD 0.99 billion by 2034. At 88.41% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Against regional totals of USD 0.69 billion in 2025 and USD 1.13 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in the United States is the global one: 37.58% of 2025 revenue in DNA Microarrays, 33.89% by 2034, against 8.56% growth in Tissue Microarrays taking it from 7.88% to 9.06%. Its 88.41% weight in North America means those movements carry straight into the regional totals. Revenue by type for the United States is reported separately in the full report.

The Food and Drug Administration regulates microarray platforms intended for clinical or diagnostic use as in vitro diagnostic devices under its medical device framework. A manufacturer must first establish the correct risk classification, since that determines whether premarket clearance or a more rigorous approval pathway applies before the product reaches the market. Platforms labelled strictly for research use and not intended to guide a clinical decision generally sit outside this premarket requirement. Cleared or approved systems remain subject to the FDA's quality system regulation covering design controls and manufacturing, plus labelling requirements that state intended use and performance limitations plainly.

Competition in the United States runs between the suppliers this study tracks: Thermo Fisher Scientific, Agilent, Sequenom, Roche NimbleGen, Illumnia, Applied Microarrays, BioMerieux SA, Discerna, Gyros AB, Luminex Corporation, NextGen Sciences, ProteoGenix and And Others.. DNA Microarrays, at 37.58% of 2025 revenue, is where the volume sits, and Tissue Microarrays, growing at 8.56%, is where position changes hands over the forecast period. Country-level shares and positioning per company sit in the full report.

Canada is sized at USD 0.08 billion in 2025, rising to USD 0.14 billion by 2034; 4.85% of global revenue and 11.59% of North America. It is reported separately from the United States across every segmentation axis in the full report.

In Europe, 26.9% of global revenue puts 2025 at USD 0.44 billion and reaches USD 0.75 billion by 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

25% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

DNA Microarrays leads here as it does globally, at 37.58% of 2025 revenue, and Tissue Microarrays again grows fastest at 8.56%. The full report breaks Europe out along every axis and by country.

USD 0.13 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 0.23 billion by 2034. Its 29.55% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 0.44 billion and USD 0.75 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is DNA Microarrays at 37.58% of 2025 revenue, easing to 33.89% by 2034, and the fastest is Tissue Microarrays at 8.56%, from 7.88% to 9.06%. Its 29.55% weight in Europe means those movements carry straight into the regional totals. Germany carries its own type breakdown in the full report.

In Germany, microarray products used for clinical diagnosis fall under the EU In Vitro Diagnostic Regulation, administered nationally by the Federal Institute for Drugs and Medical Devices alongside notified bodies that assess conformity for higher-risk categories. A supplier must classify the product according to its intended purpose and the risk it poses to patient management, since that classification decides whether a notified body must review the technical file before CE marking can be applied. Performance evaluation, traceability through a unique device identifier, and post-market surveillance obligations all apply once the device is placed on the market. Products intended only for research use, outside a diagnostic claim, are not subject to this regime, though marketing them still requires labelling that makes that restriction clear.

Thermo Fisher Scientific, Agilent, Sequenom, Roche NimbleGen, Illumnia, Applied Microarrays, BioMerieux SA, Discerna, Gyros AB, Luminex Corporation, NextGen Sciences, ProteoGenix and And Others. are the suppliers covered in Germany. Two different problems sit on the same axis: holding DNA Microarrays at 37.58% of 2025 revenue, and taking Tissue Microarrays while it grows at 8.56%. The commercial size of that position is USD 0.44 billion in 2025 and USD 0.75 billion by 2034, 26.9% of the global total in the base year.

Within Europe, the United Kingdom accounts for 25% of regional revenue and 6.67% of the global total, worth USD 0.11 billion in 2025 and USD 0.2 billion by 2034.

4.85% of global revenue is generated in France; USD 0.08 billion in 2025, reaching USD 0.14 billion in 2034, and 18.18% of Europe.

USD 0.38 billion of 2025 revenue is generated in Asia Pacific, 22.9% of the global microarrays market and reaches USD 0.83 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

Share climbs to 28% by 2034, on growth above the market's own 6.8%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The type mix reported at global level applies here, with DNA Microarrays the largest line at 37.58% of 2025 revenue and Tissue Microarrays the fastest-growing at 8.56%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

USD 0.14 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 0.32 billion by 2034. 36.84% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 0.38 billion to USD 0.83 billion over the same period, and this is the market carrying the country-level detail in the full report.

China buys along the same lines as the market globally; DNA Microarrays first at 37.58% of 2025 revenue and 33.89% in 2034, Tissue Microarrays fastest at 8.56% on a share moving from 7.88% to 9.06%. Because the country carries 36.84% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. China carries its own type breakdown in the full report.

China's National Medical Products Administration regulates microarray-based diagnostic products as medical devices, requiring registration before a supplier may market or sell the device domestically. The classification assigned to a given platform depends on its intended clinical use and the risk associated with an incorrect result, and higher-risk categories require a more extensive clinical evaluation dossier submitted to the regulator. Imported devices typically need a local agent responsible for regulatory compliance and post-market reporting, and labelling must appear in Chinese alongside the manufacturer's original instructions for use. Microarrays sold purely for laboratory research, without a diagnostic claim, do not require this registration, though such products still cannot be marketed with language suggesting clinical use.

Thermo Fisher Scientific, Agilent, Sequenom, Roche NimbleGen, Illumnia, Applied Microarrays, BioMerieux SA, Discerna, Gyros AB, Luminex Corporation, NextGen Sciences, ProteoGenix and And Others. are the suppliers covered in China. DNA Microarrays, at 37.58% of 2025 revenue, is where the volume sits, and Tissue Microarrays, growing at 8.56%, is where position changes hands over the forecast period. Weighting toward Asia Pacific means competing for 22.9% of 2025 global revenue, a base of USD 0.38 billion moving to USD 0.83 billion across the forecast period.

Within Asia Pacific, Japan accounts for 28.95% of regional revenue and 6.67% of the global total, worth USD 0.11 billion in 2025 and USD 0.25 billion by 2034.

3.64% of global revenue is generated in India; USD 0.06 billion in 2025, reaching USD 0.13 billion in 2034, and 15.79% of Asia Pacific.

Latin America holds 4.7% of the global microarrays market in 2025, worth USD 0.08 billion with USD 0.15 billion projected for 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

5% of global revenue sits here by 2034, up from the 2025 level, so the region grows faster than the market's 6.8% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

DNA Microarrays leads here as it does globally, at 37.58% of 2025 revenue, and Tissue Microarrays again grows fastest at 8.56%. Per-axis and per-country detail for Latin America sits in the full report.

USD 0.04 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 0.08 billion by 2034. 50% of the region in the base year makes it the largest market here without making it the region. Set against USD 0.08 billion and USD 0.15 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Demand in Brazil follows the type mix reported at global level: DNA Microarrays is the largest line at 37.58% of 2025 revenue, moving to 33.89% by 2034, while Tissue Microarrays grows fastest at 8.56% and takes its share from 7.88% to 9.06%. With 50% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Brazil by type separately.

Brazil's National Health Surveillance Agency, ANVISA, governs microarray platforms marketed for diagnostic use as in vitro diagnostic medical devices, requiring product registration before commercial distribution. A supplier must demonstrate conformity with the agency's technical requirements for manufacturing and quality management, and higher-risk diagnostic claims call for a more detailed technical dossier and, in some cases, local clinical data. Imported devices generally require a Brazilian registration holder who assumes responsibility for regulatory compliance and adverse event reporting. Labelling and instructions for use must be provided in Portuguese and state the intended purpose and limitations of the test. Products distributed solely for research purposes, without a diagnostic indication, fall outside this registration requirement.

Thermo Fisher Scientific, Agilent, Sequenom, Roche NimbleGen, Illumnia, Applied Microarrays, BioMerieux SA, Discerna, Gyros AB, Luminex Corporation, NextGen Sciences, ProteoGenix and And Others. are the suppliers covered in Brazil. DNA Microarrays, at 37.58% of 2025 revenue, is where the volume sits, and Tissue Microarrays, growing at 8.56%, is where position changes hands over the forecast period. The commercial size of that position is USD 0.08 billion in 2025 and USD 0.15 billion by 2034, 4.7% of the global total in the base year.

Within Latin America, Mexico accounts for 37.5% of regional revenue and 1.82% of the global total, worth USD 0.03 billion in 2025 and USD 0.05 billion by 2034.

In Middle East and Africa, 3.7% of global revenue puts 2025 at USD 0.06 billion on the way to USD 0.12 billion by 2034. Among the five regions it ranks fifth by revenue in both years.

Share climbs to 4% by 2034, so the region grows faster than the market's 6.8% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: DNA Microarrays largest at 37.58% of 2025 revenue, Tissue Microarrays fastest at 8.56%. Per-axis and per-country detail for Middle East and Africa sits in the full report.

Saudi Arabia is the largest market within Middle East and Africa, generating USD 0.03 billion in 2025 and projected to reach USD 0.05 billion by 2034. At 50% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 0.06 billion in 2025 and USD 0.12 billion in 2034, it is the country the full report breaks out in detail.

Saudi Arabia buys along the same lines as the market globally; DNA Microarrays first at 37.58% of 2025 revenue and 33.89% in 2034, Tissue Microarrays fastest at 8.56% on a share moving from 7.88% to 9.06%. With 50% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Saudi Arabia carries its own type breakdown in the full report.

In Saudi Arabia, the Saudi Food and Drug Authority regulates microarray-based diagnostic devices under its medical device framework, requiring establishment licensing for local manufacturers or distributors and registration of the device itself before it may be marketed. Classification follows the risk the result poses to patient management, and higher-risk diagnostic categories require a more thorough technical file and conformity assessment before the authority will list the product on its national registry. Devices already approved by a recognized reference regulator can often draw on that prior review to support the Saudi submission, though local registration remains mandatory. Labelling must appear in Arabic alongside English and state the intended use, and products marketed strictly for research use fall outside this device registration pathway.

In Saudi Arabia the field is Thermo Fisher Scientific, Agilent, Sequenom, Roche NimbleGen, Illumnia, Applied Microarrays, BioMerieux SA, Discerna, Gyros AB, Luminex Corporation, NextGen Sciences, ProteoGenix and And Others.. Volume sits in DNA Microarrays at 37.58% of 2025 revenue; movement sits in Tissue Microarrays at 8.56% growth. The commercial size of that position is USD 0.06 billion in 2025 and USD 0.12 billion by 2034, 3.7% of the global total in the base year.

South Africa is sized at USD 0.02 billion in 2025, rising to USD 0.04 billion by 2034; 1.21% of global revenue and 33.33% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, product, end-use, application, technology, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.